GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody ...

GSK is also playing up Nucala’s ability to help COPD patients avoid hospitalization, which often marks a severe turn in a person’s prognosis.

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review its application to expand the use of Nucala (mepolizumab), a monoclonal antibody that targets ...

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype ...

GSK plc (LSE/NYSE: LON: GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical (TASE: ...

Nucala is currently approved for use in China across three interleukin-5 mediated conditions. IL-5 is a key cytokine in type 2 inflammation which is an underlying driver in many diseases, GSK said.

GSK's Nucala COPD treatment under review in China Editor Ahmed Abdulazez Abdulkadir SEC Filings Published 02/20/2025, 09:18 AM ...